Avidity Biosciences, Inc.RNA

時価総額

$90.8億

PER

AOCプラットフォームによる核酸医薬開発の有力企業。AOC技術を用いたオリゴ核酸薬と3候補の臨床開発を展開。2023年11月にBMSが約1億ドルで出資。米国・欧州を中心、本社はカリフォルニア州サンディエゴ所在。

	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-44	-118	-174	-212	-322
Depreciation	0	1	1	2	3
Stock-based compensation expense	4	17	27	38	51
Amortization of premiums and discounts on marketable securities, net	-0	-0	1	11	21
Noncash operating lease costs	-	-	-	3	3
Prepaid and other assets	2	3	7	3	25
Accounts payable and accrued liabilities	6	6	18	2	35
Accrued compensation	2	6	2	3	-11
Operating lease liabilities	-	-	-	-3	-4
Deferred revenue	-	-	-5	63	-10
Net cash used in operating activities	-37	-95	-136	-119	-301
Purchases of marketable securities	-	-	-	461	1,434
Maturities of marketable securities	-	-	-	335	586
Purchases of property and equipment	1	4	3	4	7
Net cash used in investing activities	-8	-83	-190	-130	-854
Proceeds from Issuance of Common Stock	-	-	519	61	762
Proceeds from Issuance of Private Placement	-	-	-	31	238
Proceeds from Issuance of Warrants	-	-	-	-	141
Proceeds from the issuance of common stock under employee incentive equity plans	-	-	1	2	50
Net cash provided by financing activities	272	176	346	94	1,192
Net increase (decrease) in cash, cash equivalents and restricted cash	227	-1	20	-155	37
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	1	12	-	2	-
Capital Expenditures Incurred but Not yet Paid	0	0	0	-	3